BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Uterine Cancer Market Spotlight

March 13, 2019

Uterine cancer is the most prevalent type of reproductive system cancer in women. It develops when the healthy cells of the uterus transform and grow uncontrollably to form a tumor. Uterine cancer is classified into two categories: adenocarcinoma and sarcoma. Adenocarcinoma develops from the endometrial cells and accounts for more than 80% of uterine cancers. This is commonly known as endometrial cancer. One common form of endometrial adenocarcinoma is endometrioid carcinoma, for which the treatment depends on the grade of the tumor, the stage or the extent of the disease, and how far the tumor goes into the uterus. A less common form of endometrial adenocarcinoma is endometrial serous carcinoma. Sarcoma develops in the uterine glands’ supporting tissues or in the myometrium, and accounts for approximately 2–4% of uterine cancers. Types of endometrial sarcoma include endometrial stromal sarcoma and leiomyosarcoma.

This Datamonitor Healthcare report contains a Market Spotlight module.
Indications Covered: Uterine (Endometrial) Cancer
Back to the top Back to the top